trending Market Intelligence /marketintelligence/en/news-insights/trending/Y_Rx64GCof0Vs_3LGlEjzQ2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Omeros, Endo reach settlement over eye drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Omeros, Endo reach settlement over eye drug

Endo International plc reached a settlement agreement with Omeros Corp., agreeing not to launch a generic version of the Omidria eye drug before April 1, 2032.

Omeros sued the company after it filed an application seeking approval from the U.S. Food and Drug Administration to market a generic version of the medicine.

Omeros said the abbreviated new drug application infringed on its patents covering Omidria.

Endo acknowledged the validity of the patents and also agreed to pay a 15% royalty on the sales of its generic drug once it enters the market up until the last of the patents covering Omidria expires Oct. 23, 2033.